BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:SHR4640 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of SHR4640\, from ClinicalTrials.gov estimat
 es.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07362355-11088@assetmemo.bio
DTSTAMP:20261121T004531Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:SHR4640: Phase 2 readout est. (NCT07362355)
DESCRIPTION:SHR4640\, phase 2\, Gout.\nStudy: The Efficacy and Safety of SH
 R4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Pr
 imary Gout and Hyperuricemia\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/shr4640#upcoming-events\
 nRegistry record: https://clinicaltrials.gov/study/NCT07362355
URL:https://assetmemo.bio/drug/shr4640#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
